Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Author:
Publisher
BMJ
Subject
Gastroenterology
Reference22 articles.
1. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004
2. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005
3. A Review of CT-P13: An Infliximab Biosimilar;McKeage;BioDrugs,2014
4. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study;Yoo;Ann Rheum Dis,2013
5. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study;Park;Ann Rheum Dis,2013
Cited by 154 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13
2. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01
3. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study;Digestive and Liver Disease;2024-01
4. Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study;F1000Research;2023-12-06
5. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective;BioDrugs;2023-08-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3